Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SRx Health Solutions (SRXH) Total Non-Current Liabilities (2019 - 2025)

SRx Health Solutions (SRXH) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $4.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities fell 41.27% year-over-year to $4.5 million, compared with a TTM value of $4.5 million through Sep 2025, down 41.27%, and an annual FY2025 reading of $4.5 million, changed N/A over the prior year.
  • Total Non-Current Liabilities was $4.5 million for Q3 2025 at SRx Health Solutions, down from $5.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $30.3 million in Q1 2021 and bottomed at $5000.0 in Q4 2024.
  • Average Total Non-Current Liabilities over 5 years is $7.3 million, with a median of $7.6 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities tumbled 99.55% in 2024, then surged 15459.46% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $9.4 million in 2021, then increased by 22.49% to $11.6 million in 2022, then crashed by 99.42% to $67000.0 in 2023, then crashed by 92.54% to $5000.0 in 2024, then soared by 88940.0% to $4.5 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for SRXH at $4.5 million in Q3 2025, $5.8 million in Q2 2025, and $5000.0 in Q1 2025.